Andy Studna

Industry experts discuss the use of decentralized technologies and the potential of artificial intelligence in reaching underrepresented patient populations.

Palmese, executive director, site relationships and DCT solutions, discusses the practice of incorporating decentralized elements in a study rather than planning a decentralized trial from the start.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, touches on the challenges with hand-written data collection and how they can be addressed with AI.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, talks secure data transfer and risk mitigation.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), discusses how some stakeholders view DCTs only as fully remote trials.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), shares her most important takeaways from the event including how industry is becoming more and more ready to adopt decentralized elements.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights challenges with technology adoption including how sites may be asked to work with a variety of different providers.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), discusses several initiatives DTRA is working on to keep sites in-the-know on DCT elements included in study protocols.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights how DTRA is working with sites and sponsors to gauge the feasibility of site-validated technology use.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), looks forward and shares her thoughts on future trends with clinical technology.